Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393089 | 0.94 | ADRA1D (0.62) | ADRA1AADRA1DADRA1BDRD2SIGMAR1 | |
| SCHEMBL17549666 | 0.91 | SIGMAR1 (0.73) | ADRA1AADRA1DADRA1BSIGMAR1HTR1A | |
| SCHEMBL20254428 | 0.85 | MEN1 (0.78) | ADRA1ADRD2HTR2AHTR1ADRD3 | |
| SCHEMBL13925152 | 0.85 | ADRA1A (0.58) | ADRA1AADRA1DADRA1BDRD2HTR1A | |
| Hydrochloric Acid SCHEMBL11635528 | 0.85 | ADRA1D (0.66) | ADRA1AADRA1DADRA1BDRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL30658979 | 0.84 | MEN1 (0.76) | ADRA1ADRD2HTR2AHTR1ADRD3 | |
| SCHEMBL11372803 | 0.84 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BDRD2SIGMAR1 | |
| SCHEMBL11402919 | 0.84 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BDRD2SIGMAR1 | |
| SCHEMBL9050713 | 0.83 | CCR3 (0.66) | ADRA1AADRA1DADRA1BSIGMAR1 | |
| SCHEMBL10603564 | 0.83 | ALDH1A1 (0.81) | ADRA1AADRA1DADRA1BDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498443-B2 | Process for production of carebastine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-03-03 | — | — | US | claimed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | ADRA1A 161/4885ADRA1D 199/4885ADRA1B 348/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | ADRA1A 161/4885ADRA1D 199/4885ADRA1B 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.